Pacer Advisors Inc. Boosts Position in Charles River Laboratories Intl. Inc (CRL)

Share on StockTwits

Pacer Advisors Inc. increased its position in Charles River Laboratories Intl. Inc (NYSE:CRL) by 13.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,271 shares of the medical research company’s stock after purchasing an additional 2,112 shares during the period. Pacer Advisors Inc.’s holdings in Charles River Laboratories Intl. were worth $2,324,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. The Manufacturers Life Insurance Company grew its stake in Charles River Laboratories Intl. by 4.2% in the third quarter. The Manufacturers Life Insurance Company now owns 79,600 shares of the medical research company’s stock worth $10,709,000 after purchasing an additional 3,197 shares in the last quarter. Paloma Partners Management Co acquired a new position in Charles River Laboratories Intl. in the third quarter worth about $1,010,000. Jane Street Group LLC grew its stake in Charles River Laboratories Intl. by 151.9% in the third quarter. Jane Street Group LLC now owns 13,309 shares of the medical research company’s stock worth $1,791,000 after purchasing an additional 8,025 shares in the last quarter. Aristotle Capital Boston LLC grew its stake in Charles River Laboratories Intl. by 4.4% in the third quarter. Aristotle Capital Boston LLC now owns 125,671 shares of the medical research company’s stock worth $16,908,000 after purchasing an additional 5,272 shares in the last quarter. Finally, Jefferies Group LLC grew its stake in Charles River Laboratories Intl. by 34.9% in the third quarter. Jefferies Group LLC now owns 4,912 shares of the medical research company’s stock worth $661,000 after purchasing an additional 1,271 shares in the last quarter. Institutional investors and hedge funds own 96.19% of the company’s stock.

A number of equities analysts recently commented on the company. Morgan Stanley lifted their price target on Charles River Laboratories Intl. from $102.00 to $112.00 and gave the stock a “hold” rating in a research note on Tuesday, September 11th. Raymond James upgraded Charles River Laboratories Intl. from a “market perform” rating to an “outperform” rating and set a $140.00 price target for the company in a research note on Thursday, August 23rd. Credit Suisse Group decreased their price target on Charles River Laboratories Intl. from $129.00 to $121.00 and set a “neutral” rating for the company in a research note on Tuesday, August 21st. UBS Group assumed coverage on Charles River Laboratories Intl. in a research note on Tuesday, October 9th. They issued a “neutral” rating and a $140.00 price target for the company. Finally, ValuEngine upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research note on Tuesday, September 11th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $132.06.

Shares of CRL stock opened at $124.96 on Friday. The company has a debt-to-equity ratio of 1.32, a current ratio of 1.55 and a quick ratio of 1.32. Charles River Laboratories Intl. Inc has a 52 week low of $96.70 and a 52 week high of $139.72. The company has a market capitalization of $6.01 billion, a price-to-earnings ratio of 21.07, a P/E/G ratio of 1.76 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, November 7th. The medical research company reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.15. Charles River Laboratories Intl. had a return on equity of 25.08% and a net margin of 6.39%. The company had revenue of $585.30 million during the quarter, compared to the consensus estimate of $567.58 million. During the same period in the previous year, the firm posted $1.30 earnings per share. Charles River Laboratories Intl.’s quarterly revenue was up 26.1% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories Intl. Inc will post 5.93 earnings per share for the current fiscal year.

In other news, Chairman James C. Foster sold 1,977 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, December 10th. The stock was sold at an average price of $129.11, for a total transaction of $255,250.47. Following the sale, the chairman now owns 267,676 shares of the company’s stock, valued at $34,559,648.36. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David P. Johst sold 23,356 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $136.00, for a total value of $3,176,416.00. Following the sale, the insider now directly owns 219,849 shares in the company, valued at approximately $29,899,464. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,639 shares of company stock valued at $4,142,794. 2.10% of the stock is currently owned by insiders.

WARNING: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/12/16/pacer-advisors-inc-boosts-position-in-charles-river-laboratories-intl-inc-crl/3084887.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: How to Invest in an Index Fund

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.